Business
Medicure Announces Settlement of Patent Infringement Action
Medicure Announces Settlement of Patent Infringement Action Canada NewsWire ...
About this update from Medicure Inc.
[{"type":"text","content":"\n \n \n \n Medicure Announces Settlement of Patent Infringement Action\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n WINNIPEG, MB, Nov. 18, 2020\n \n \n \n \n \n WINNIPEG, MB\n \n ,\n \n Nov. 18, 2020\n \n /CNW/ - Medicure Inc. (\"Medicure\" or the \"Company\") (TSXV: MPH) (OTC: MCUJF), a cardiovascular pharmaceutical company, today announces that its subsidiary, Medicure International Inc., has settled its ongoing patent infringement action against Nexus Pharmaceuticals, Inc. (\"Nexus\") in the U.S. District Court for the Northern District of\n \n Illinois\n \n , which alleged infringement of Medicure's U.S. Patent No. 6,770,660 (\"the '660 patent\"). As part of the settlement, Nexus has acknowledged that the '660 patent is valid, enforceable and infringed. The settlement results in the Company entering into a license agreement with Nexus with anticipated launch dates for Nexus' generic products of November 1, 2022 for the 5 mg strength and\n \n January 1, 2023\n \n for the 12.5 mg strength. The remaining terms of the settlement are confidential.\n \n \n \"We are pleased that we were able to settle this litigation in a cost-effective manner while protecting our AGGRASTAT brand and its intellectual property.\" stated Dr.\n \n Albert Friesen\n \n , Chief Executive Officer of the Company and Chair of its Board of Directors.\n \n \n The Company had filed the patent infringement action against Nexus alleging infringement of the '660 patent. The patent infringement action was in response to Nexus' filing of an abbreviated new drug application (ANDA) seeking approval from the U.S. Food and Drug Administration (\"FDA\") to market a generic version of AGGRASTAT\n \n ®\n \n (tirofiban hydrochloride) injection before the expiration of the '660 patent. The '660 patent is listed in the FDA's orange book with an expiry date of\n \n May 1, 2023\n \n .\n \n \n AGGRASTAT\n \n ®\n \n is a platelet aggregation inhibitor indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardi...